Figure INF-6 Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (iii) New injecting drug users (injecting less than 2 years), 2003 to 2004

Figure INF-06 part iii

Notes:

Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary and some sample sizes are small.

Data for Belgium, Austria and Slovenia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. Data for UK are based on IDUs injecting less than 3 years.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-13.